Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Annals of Oncology ◽

10.1093/annonc/mdt228 ◽

2013 ◽

Vol 24 (9) ◽

pp. 2396-2402 ◽

Cited By ~ 20

Author(s):

B. Melichar ◽

S. Bracarda ◽

V. Matveev ◽

B. Alekseev ◽

S. Ivanov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Low Dose ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Interferon Α2a ◽

BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4546 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4546-4546 ◽

Cited By ~ 7

Author(s):

B. Melichar ◽

S. Bracarda ◽

V. Matveev ◽

I. Rusakov ◽

A. Kaprin ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Prospective Study ◽

Cell Carcinoma ◽

Renal Cell ◽

Low Dose ◽

First Line ◽

Safety And Efficacy ◽

Interferon Α2a

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

Therapeutic Advances in Urology ◽

10.1177/17562872211029784 ◽

2021 ◽

Vol 13 ◽

pp. 175628722110297

Author(s):

Giandomenico Roviello ◽

Sebastiano Buti ◽

Carlo Cattrini ◽

Alessia Mennitto ◽

Carlo Messina ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Tyrosine Kinase Inhibitors ◽

Renal Cell ◽

Kinase Inhibitors ◽

Line Treatment ◽

First Line ◽

Increased Risk ◽

A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2021.03.016 ◽

2021 ◽

Author(s):

Irbaz Bin Riaz ◽

Huan He ◽

Alexander J. Ryu ◽

Rabbia Siddiqi ◽

Syed Arsalan Ahmed Naqvi ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Line Treatment ◽

First Line ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

PharmacoEconomics ◽

10.1007/s40273-012-0006-5 ◽

2012 ◽

Vol 31 (1) ◽

pp. 15-24 ◽

Cited By ~ 21

Author(s):

Mary Kilonzo ◽

Jenni Hislop ◽

Andrew Elders ◽

Cynthia Fraser ◽

Donald Bissett ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2015.1058359 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1915-1927 ◽

Cited By ~ 15

Author(s):

James Larkin ◽

Abby Paine ◽

Grace Foley ◽

Stephen Mitchell ◽

Connie Chen

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Meta Analysis ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES

Current Opinion in Urology ◽

10.1097/mou.0000000000000207 ◽

2015 ◽

Vol 25 (5) ◽

pp. 395-401 ◽

Cited By ~ 6

Author(s):

Manuela Schmidinger ◽

Janet Wittes

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

How does vaccine treatment compare with standard targeted therapy for first-line treatment of people with metastatic renal cell carcinoma?

Cochrane Clinical Answers ◽

10.1002/cca.2631 ◽

2019 ◽

Author(s):

Jane Burch ◽

Gustavo Villalobos

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Vaccine Treatment ◽

Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis

Translational Andrology and Urology ◽

10.21037/tau-20-969 ◽

2021 ◽

Vol 10 (1) ◽

pp. 300-309

Author(s):

Yingwei Xie ◽

Zhiliang Chen ◽

Qiyu Zhong ◽

Yuqing Chen ◽

Wentai Shangguan ◽

...

Keyword(s):

Systematic Review ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Checkpoint Inhibitors ◽

Meta Analysis ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽